For two years, Ovid spun a Phase II miss as a win. The drug just failed Phase III

Two years ago, Ovid’s lead pro­gram failed in Phase II. Or at least that’s what an­a­lysts said.

Je­re­my Levin, the com­pa­ny’s CEO, ar­gued in­vestors mis­un­der­stood …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER